We focused our previous studies11 on tumor cells expressing the wild-type NAT2*4 (rapid) or the NAT2*6 (slow) acetylator allele, and it is currently unknown which, if any, alleles arising from the compendium of NAT2 slow acetylator variants that can be exploited in LOH-based therapy using APA. This evidence concerns the gene NAT2 and neoplasm.